Cenobamate in brain tumor‐related epilepsy: A multicenter real‐world experience
OBJECTIVE: Cenobamate (CNB) is a novel antiseizure medication with a dual mechanism of action that has demonstrated high efficacy in drug-resistant focal epilepsy; however, evidence in brain tumor-related epilepsy (BTRE) remains limited. The study aimed to evaluate the effectiveness, safety, and tolerability of CNB as add-on therapy in a multicenter cohort of patients with BTRE. METHODS: We conducted a multicenter, retrospective observational study across tertiary epilepsy centers in the Lazio region, Italy. Adult patients with drug-resistant BTRE treated with CNB as adjunctive therapy were included. Seizure frequency was assessed at baseline and during follow-up. Primary outcomes were changes in monthly seizure frequency and responder rates. Effectiveness was analyzed in both the overall population and in a homogeneous cohort of patients with 6-month follow-up. RESULTS: Twenty patients (10 females, median age 48 years) were included. Tumor histology included meningioma (n = 7, 35%), astrocytoma (n = 4, 20%), glioblastoma (n = 3, 15%), ganglioglioma (n = 3, 15%), oligodendroglioma (n = 2, 10%), and dysembryoplastic neuroepithelial tumor (n = 1, 5%). In the overall analysis population (n = 20), after a median 12-month follow-up, median seizure frequency significantly decreased from 6 to 1 per month (p < 0.001), with a median reduction of 85.8% (IQR 51.4-96.7). Responder rates were 80% (≥50% seizure reduction), 60% (≥75%), and 20% achieved seizure freedom. Adverse events occurred in 12 patients (60%), including sedation (n = 8, 40%), postural instability (n = 3, 15%), diarrhea, and mild cutaneous rash (n = 1, 5% each). CNB was discontinued in one patient (5%). SIGNIFICANCE: In this multicenter real-world cohort of patients with drug-resistant BTRE and heterogeneous tumor histology, CNB was associated with a reduction in seizure frequency and was well tolerated. PLAIN LANGUAGE SUMMARY: Seizures caused by brain tumors can be difficult to control. We reviewed records from 20 adults who received cenobamate alongside their existing seizure medicines. At their last follow-up, 16 had at least half as many seizures, and four were seizure-free. Twelve patients experienced side effects, most commonly sleepiness; one stopped cenobamate because of a rash. These findings suggest that cenobamate may help some people with brain tumor-related epilepsy. However, the study was small, had no comparison group, and included patients with different tumors and follow-up durations. Larger studies are needed.
Authors
- Patrizia Pulitano (ORCID: https://orcid.org/0000-0001-6602-779X)
- Marta Piccioli (ORCID: https://orcid.org/0000-0002-7953-0906)
- Mariana Fernandes (ORCID: https://orcid.org/0000-0002-7005-2805)
- Marina Romozzi (ORCID: https://orcid.org/0000-0001-6016-3141)
- Paolo Tisei
- Catello Vollono (ORCID: https://orcid.org/0000-0001-9371-8035)
- Paolo Calabresi (ORCID: https://orcid.org/0000-0003-0326-5509)
- Claudio Liguori (ORCID: https://orcid.org/0000-0003-2845-1332)
- Giulia Lippa (ORCID: https://orcid.org/0009-0001-4522-680X)
- Maria Antonietta Bassetti
- Matteo Antonucci
- Marta Maschio
- Mario Tombini
- Giovanni Assenza
- Adolfo Mazzeo
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Rome Tor Vergata (IT)
- Università Campus Bio-Medico (IT)
- Azienda Ospedaliera San Giovanni Addolorata (IT)
- Agostino Gemelli University Polyclinic (IT)
- ASL Roma (IT)
- Ospedale San Filippo Neri (IT)
- Policlinico Tor Vergata (IT)
- Campus Bio Medico University Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Epilepsia Open
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1002/epi4.70365
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00